CS585
Additional data strengthens Cereno's CS1 in PAH
Following promising Phase IIa results for the drug candidate CS1 against pulmonary arterial hypertension (PAH) in October 2024, Cereno Scientific is now delivering...
Cereno Scientific to evaluate CS1 with advanced imaging technology
Cereno Scientific announces that a substudy with CS1...
Significant third quarter for Cereno
Cereno Scientific delivered a strong Q3 2024, not...
The temperature at Cereno Scientific after significant news
Cereno Scientific has recently announced the selection of a...
Cereno signs license agreement with University of Michigan
Cereno Scientific reports continued progress in the company's plan...
Cereno Scientific's CBO on his new role
Cereno Scientific's clinical and preclinical programs in cardiovascular...
Cereno launches knowledge videos through Insights Series
Cereno Scientific wants to increase awareness of its portfolio...
Cereno's CIPO comments on the company's strong patent portfolio
Patent protection is crucial for all companies in life...
Cereno Scientific summarizes Q3
The reporting season is in full swing and during the day...
Cereno presents promising data for preclinical CVD candidate
In June, Cereno Scientific presented preclinical data regarding...
First patient recruited to Cereno Scientific's Phase II study
Cereno Scientific has announced that the first patient...
BioStock Studio: Cereno Scientific summarizes the first quarter of the year
Sten R Sorensen